New York City’s Pandemic Response Lab was supposed to be the “gold standard” for COVID-19 testing. Yet, the world learned of New York City’s first Omicron patient from public health officials in Minnesota.
Continue reading
Jonathan Brennan-Badal is CEO of Opentrons, the parent company of the Pandemic Response Lab. The valuation of Opentrons has increased 20-fold from $90 million to $1.8 billion since winning Government COVID-19 testing contracts from the City of New York. It also sequences tests for Coronavirus variants. Its record on sequencing has raised a lot of questions. NYC Mayor's Office (YouTube/Fair Use)